Orion Corporation Discloses Manager Transactions
Orion Corporation has recently shared significant updates regarding transactions made by its executives, particularly focusing on the actions of Chief Executive Officer, Liisa Hurme. This disclosure is part of compliance with the Market Abuse Regulation (EU) No 596/2014, which mandates transparency in trading activities involving shares and linked securities by company insiders.
Details of the Transaction
The announcement detailed an initial notification concerning the receipt of share-based incentives. On March 10, Liisa Hurme was granted a total of 17,000 shares as part of her incentive package, marking a notable transaction within the corporate structure of Orion Corporation. Notably, these transactions are categorized as taking place outside of a trading venue, indicating that they were not conducted on a stock exchange. The instrument type involved in this transaction is classified as shares, and further information includes the corresponding ISIN FI0009014377.
Managerial Insights
Liisa Hurme, with an established career in the pharmaceutical industry, has been pivotal in guiding Orion Corporation through various strategic directions. The report outlines her role as a major player in the company's decision-making processes, reinforcing the trust and responsibility placed in executives to manage shareholder interests effectively. Her participation in share incentive programs is a testament to Orion’s commitment to aligning executive performance with shareholder value.
About Orion Corporation
For over a century, Orion Corporation has made significant strides in the pharmaceutical landscape, dedicated to improving well-being worldwide. The Finnish-based company specializes in both human and veterinary pharmaceuticals, in addition to active pharmaceutical ingredients. Orion boasts an extensive array of proprietary and generic medicines alongside consumer health products. The core therapeutic areas of its research and development (R&D) encompass oncology and pain management, leading to the creation of essential medicines for treating various major health conditions, including cancer and neurological disorders.
Recent Financial Performance
In recent years, Orion has demonstrated robust financial performance, with net sales reported at EUR 1,542 million in 2024. The company employs approximately 3,700 people, underscoring its role as a significant employer in the industry. Moreover, Orion’s stock is traded on Nasdaq Helsinki under the ticker symbol ORNBV, further enhancing its visibility in the market and enabling investors to participate in its growth.
Contact Information
For further inquiries, the company can be reached at their communications department:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Frequently Asked Questions
What was the nature of the transaction involving Liisa Hurme?
Liisa Hurme received a total of 17,000 shares as part of a share-based incentive transaction.
What is Orion Corporation known for?
Orion Corporation is a Finnish pharmaceutical company that develops and markets human and veterinary pharmaceuticals.
Where is Orion Corporation headquartered?
The headquarters of Orion Corporation is located at Orionintie 1A, FI-02200 Espoo, Finland.
How has Orion Corporation performed financially?
In 2024, Orion reported net sales of EUR 1,542 million, showcasing strong financial growth.
On what stock exchange are Orion's shares listed?
Orion's A and B shares are listed on Nasdaq Helsinki under the ticker ORNBV.
